Stent Thrombosis: Incidence, Predictors and New Technologies

Table 5

A table to illustrate ongoing studies utilizing the results of platelet reactivity testing to assess outcomes following PCI.

Study	Number of patients	Patient population	Platelet reactivity value	Antiplatelet therapy	Primary endpoint
ARCTIC	2,500	Elective PCI	<15%	GPIIb/IIIa inhibitors	Death, MI, Stroke, TVR, ST
DANTE	442	NSTEMI	PRU > 240	Clopidogrel 75 mg versus Clopidogrel 150 mg	Cardiovascular death, MI and TVR

ARCTIC: Monitored Adjusted Antiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation and Interruption Versus Continuation of Double Antiplatelet Therapy; DANTE: Dual Antiplatelet Therapy Tailored on the Extent of Platelet Inhibition; PCI: percutaneous coronary intervention; NSTEMI: Non-ST elevation myocardial infarction; GPIIb/IIIa: Glycoprotein IIb/IIIa inhibitor; MI: myocardial infarction; TVR: target vessel revascularization; ST: stent thrombosis; PRU: P2YC12 reaction unit.